Castañeda Hernández S1,3, De la Cruz Durán H1,3, García López IE2, Pérez Morales ME1, Sánchez Palacio JL1
1 Facultad Ciencias Químicas e Ingeniería. Universidad Autónoma de Baja California. Tijuana B.C. (México)
2 Derpartamento de Dermatología Hospital Infantil de las Californias. Tijuana B.C. (México)
3 Departamento de Farmacia. Hospital Infantil de las Californias. Tijuana B.C. (México)
Rev. OFIL 2016, 26;4:322-329
Fecha de recepción: 08/01/2016 – Fecha de aceptación: 25/10/2016
Saúl Castañeda Hernández
C/Piedra Luna, 1
21440 Tecate B.C (México)
Correo electrónico: firstname.lastname@example.org
Infantile hemangiomas are the most frequent vascular tumors of infancy they are present in 5-10 percent of children under one year of age; can be located on any part of the body surface. Propranolol is a β-blocker used to treat hypertension and other cardiovascular diseases, recently has been reported the use in reducing vascular tumors of childhood, showing superior effects to those obtained with other drugs.
The purpose of this systematic review was to examine studies of the propranolol effect in patients with this illness, published worldwide of 2010 to 2016.
In this review 15 studies published about the pharmacological effect of propranolol in patients with infantile hemangioma; were analyzed, where dose, onset of therapy, therapeutic effect and side effects to treatment are compared. In it 92% of the studies the effect of propranolol has been satisfactory with low incidence of side effects.
Key Words: Propranolol, infantile hemangioma, propranolol effect.